USP vs EP Nicotine Standards: Key Differences Explained

Manufacturers selling into both the US and EU often treat USP and EP as interchangeable. They are not. The two pharmacopoeias agree on the broad strokes but diverge on impurity thresholds, analytical methods, and identification protocols. Those differences determine whether your nicotine passes regulatory review in your target market, and getting it wrong means rejected submissions, delayed launches, and reformulation costs that nobody budgeted for.

This is not an academic distinction. If you are sourcing pure nicotine for products that cross international borders, understanding where these standards align and where they diverge is a procurement requirement, not optional reading.

Quick Orientation

USP (United States Pharmacopeia) is published by the US Pharmacopeial Convention. Its monographs define identity, strength, purity, and quality for drug substances sold in the United States. USP standards are referenced throughout FDA regulatory frameworks, including PMTA submissions for tobacco products and NDAs/ANDAs for pharmaceutical nicotine products.

EP (European Pharmacopoeia) is published by the European Directorate for the Quality of Medicines (EDQM). EP monographs are legally binding for pharmaceutical products sold in EU member states and many countries that adopt EP standards, including Switzerland, Turkey, and numerous African and Asian nations that reference the EP. The EP carries legal weight under the EU TPD for nicotine-containing consumer products as well.

Both are serious. Neither is optional if you are selling pharmaceutical nicotine in their respective jurisdictions. And if you are selling into both markets, you need to understand both.

Purity: Same Ballpark, Different Baselines

• USP requires nicotine assay of 99.0% minimum (dried basis) by potentiometric titration.
• EP specifies 98.5% to 101.0% (dried substance) by potentiometric titration in non-aqueous medium.

The EP range is wider on paper, but the testing methodology is more specific. The non-aqueous titration method specified by the EP uses glacial acetic acid as the solvent and perchloric acid as the titrant, which produces sharper endpoints for basic compounds like nicotine. USP potentiometric titration uses aqueous conditions, which can introduce more variability in endpoint detection.

In practice, any serious supplier targets 99.5%+ purity, which clears both standards with margin. But "clearing the standard" and "being certified against the standard" are two different things. Your COA needs to report results using the specific method prescribed by the monograph you are claiming compliance with.

For a broader explanation of what USP/EP grade nicotine means and why purity matters at a fundamental level, see our full explainer.

Where the Standards Actually Diverge

Impurity Limits

This is the sharpest difference between the two monographs, and the one most likely to cause problems for manufacturers who assume USP compliance automatically means EP compliance.

• USP: Individual specified impurities up to 0.5%. Total impurities up to 1.0%. Determined by HPLC (high-performance liquid chromatography).
• EP: Individual specified impurities up to 0.3%. Unspecified impurities capped at 0.10%. Total impurities up to 0.5%. Determined by GC (gas chromatography).

The EP is meaningfully more restrictive in three ways. First, it sets a lower ceiling on total impurities (0.5% vs 1.0%). Second, it imposes a lower limit on individual specified impurities (0.3% vs 0.5%). Third, and most importantly, it adds an explicit cap on unspecified impurities at 0.10% that USP does not require. Unspecified impurities are compounds detected by the analytical method that are not explicitly named in the monograph. The EP position is that any unknown compound in a pharmaceutical ingredient must be controlled, even if it has not been individually characterized.

The analytical method difference also matters. Gas chromatography and HPLC detect different compound classes with different sensitivities. GC is better suited to volatile and semi-volatile compounds, which includes many tobacco-derived impurities. HPLC is better for non-volatile and thermally labile compounds. A nicotine batch that looks clean by HPLC may show additional peaks when analyzed by GC, and vice versa.

What this means for you: nicotine that comfortably passes USP impurity testing may fail EP limits. If you are targeting European markets with products like nicotine salts or nicotine pouches, your supplier needs to test and certify against EP specifically. A USP COA alone is not sufficient for EP compliance.

Heavy Metals Testing

Another significant split that has practical implications for incoming material qualification.

• USP follows chapters 232 and 233 (Elemental Impurities): Lead at 0.5 ppm, Arsenic at 0.15 ppm, Cadmium at 0.05 ppm, Mercury at 0.03 ppm for oral drug products. These limits were established based on permitted daily exposure calculations derived from toxicological data.
• EP follows Section 2.4.8 and is increasingly aligning with ICH Q3D. Similar element-specific limits but with methodological variations in sample preparation and instrumental analysis.

The USP approach, implemented through chapters 232/233, replaced the older general heavy metals test (the sulfide precipitation test) with element-specific limits and modern analytical methods (ICP-MS and ICP-OES). This was a significant upgrade in both specificity and sensitivity. The EP has been on a parallel path, migrating from the older 2.4.8 general test toward ICH Q3D-aligned elemental impurity limits.

For practical purposes, the two frameworks are converging, but they are not yet identical. Sample preparation methods, reference standard requirements, and validation criteria still differ between the two pharmacopoeias. Your testing laboratory needs to be explicit about which protocol they are running, because a result generated under USP 233 methodology is not automatically valid for EP compliance, even if the numeric limits are similar.

The source of the nicotine matters enormously here. Tobacco grown in regions with contaminated soil concentrates heavy metals during cultivation. Suppliers with contract farming programs control soil quality from the start. Spot-market sourcing introduces heavy metal variability that no amount of downstream testing can fully mitigate.

Identification Methods

• USP: IR spectrophotometry matched against a USP Reference Standard.
• EP: IR spectrophotometry plus chemical reaction tests (precipitation with silicotungstic acid).

The EP requires an additional confirmation step beyond instrumental analysis. The silicotungstic acid precipitation test is a classical chemical identification method that confirms the presence of a basic nitrogen-containing compound consistent with nicotine. It is a belt-and-suspenders approach: the IR confirms the molecular fingerprint, and the chemical test confirms the functional group chemistry.

This rarely causes problems in practice, but it does add time and cost to qualification testing. If your incoming material testing protocol only includes IR identification (sufficient for USP), you will need to add the precipitation test for EP compliance.

Specific Optical Rotation

Both monographs require optical rotation testing to confirm the presence of natural S-(-)-nicotine rather than synthetic or racemic nicotine.

• USP: Specific rotation between -166 and -170 degrees (undiluted, 589 nm).
• EP: Specific rotation between -166 and -170 degrees, with solvent and concentration conditions specified slightly differently.

The numeric range is identical, but the measurement conditions (solvent, concentration, temperature, path length) specified in each monograph may differ, which can produce slightly different results on the same sample. Your analytical lab must follow the exact conditions specified in the monograph you are certifying against.

This test is particularly important for detecting adulteration with synthetic nicotine. Synthetic nicotine produced by chemical synthesis is typically racemic (a 50/50 mixture of S and R isomers) unless enantioselective synthesis is used. The optical rotation test catches racemic adulteration immediately. It will not, however, detect blending with enantiopure synthetic S-nicotine, which requires more sophisticated analytical approaches like chiral HPLC.

Residual Solvents

Both reference ICH Q3C guidelines for residual solvent limits, but through different chapters:

• USP uses chapter 467 methodology, which specifies headspace GC with specific column, temperature program, and calibration requirements.
• EP uses Section 2.4.24 with its own GC protocol, including different column specifications and reference solution preparations.

Same limits, different roads to get there. The ICH Q3C classification system is consistent: Class 1 solvents (benzene, carbon tetrachloride) should not be used. Class 2 solvents (hexane at 290 ppm, methylene chloride at 600 ppm) have concentration limits. Class 3 solvents (ethanol, acetone) are low-toxicity with higher permitted levels.

Your testing lab needs to run the specific method for the standard you are certifying against. A residual solvent result generated using EP 2.4.24 methodology may not be accepted as evidence of USP 467 compliance, and vice versa, even though the permissible limits are identical. This is not bureaucratic pedantry. Different sample preparation and analytical conditions can produce different results on the same material.

Water Content

Both require Karl Fischer titration but with slight methodological differences:

• USP: Water content not more than 0.5%, determined by Karl Fischer (USP chapter 921).
• EP: Water content not more than 0.5%, determined by Karl Fischer (EP 2.5.12).

The limit is the same. The methodological chapters specify different details for sample preparation, titration conditions, and endpoint criteria. In practice, this test is straightforward and results are consistent across methods, but for formal compliance, the COA should reference the correct chapter.

Which Standard Do You Need?

US market: USP compliance required for pharmaceutical products. Strongly recommended for e-liquid and nicotine pouch products to support PMTA submissions. The FDA does not technically require USP-grade nicotine for tobacco products, but applicants who use it have a clearer path through the review process because the quality parameters are already defined and accepted.

EU market: EP compliance required for pharmaceutical products. Recommended for TPD-notified products. Several EU member states have gone beyond the TPD minimum and impose pharmaceutical-grade requirements on e-liquid ingredients.

UK market: EP standards adopted. The post-Brexit regulatory framework largely mirrors TPD requirements. The UK MHRA references EP monographs for pharmaceutical-grade nicotine.

Both markets: Dual USP/EP compliance. This is the practical choice for any manufacturer with international ambitions. It also future-proofs your supply chain, since regulatory requirements tend to tighten over time, not loosen.

Other markets: Many countries reference either USP or EP as their pharmacopoeial standard. Japan uses JP (Japanese Pharmacopoeia) with its own nicotine monograph. Australia references both USP and EP. Countries in the Gulf Cooperation Council typically reference EP. Know your target market's pharmacopoeial framework before you source.

The Case for Dual Compliance

Since the EP is generally more stringent on impurity limits, pure nicotine that meets EP specifications will typically also meet USP requirements. But "typically" is not a word regulators accept. You need testing and certification against both monographs, using the specific methods prescribed by each.

Dual compliance also simplifies your supply chain. Rather than maintaining separate inventories of USP-grade and EP-grade nicotine, you stock one product that serves both markets. This reduces warehousing costs, simplifies inventory management, and eliminates the risk of using the wrong grade in production. For manufacturers producing nicotine polacrilex or nicotine bitartrate dihydrate for multiple markets, dual compliance at the raw material level cascades into dual compliance at the finished product level.

The cost premium for dual-certified nicotine over single-standard material is modest, typically 3 to 8 percent. The cost of discovering that your USP-only nicotine fails EP impurity limits after you have committed to a European product launch is substantially higher.

Common Pitfalls

Assuming USP equals EP. It does not. USP compliance does not guarantee EP compliance, particularly on impurity limits. Always request testing against the specific standard your market requires.

Accepting COAs without method references. A purity result of 99.7% is meaningless without knowing which method produced it. Was it potentiometric titration? Aqueous or non-aqueous? Against which reference standard? Insist on COAs that reference specific USP or EP chapter numbers.

Ignoring the analytical method differences. GC and HPLC see different things. A COA showing impurity results by HPLC does not satisfy EP requirements that specify GC. Make sure your supplier's analytical program matches your regulatory needs.

Not verifying reference standards. Both USP and EP require identification testing against official reference standards. USP Reference Standards and EP Chemical Reference Substances are not interchangeable. Your testing lab needs to use the correct reference material for the monograph they are certifying against.

Frequently Asked Questions